Month: May 2019

Parvus Therapeutics enters global collaboration and licensing agreement with Genentech to develop Navacim ™ Therapeutics for the treatment of autoimmune diseases

BURLINGAME, Calif. And CALGARY, Alberta – (COMMERCIAL THREAD) – Parvus Therapeutics, a biopharmaceutical company focused on the development of disease-specific immunoregulatory drugs to treat autoimmune diseases without altering normal immunity, has entered into a global collaboration and licensing agreement with group member Genentech Roche, to develop, manufacture and market novel Navacim ™ therapeutic products for […]

Back To Top